Toys Market to Garner USD 275.65 Billion Revenue by 2030 at 5.2% CAGR – Report by Market Research Future (MRFR)
Posted On June 23, 2022
[view original post
GSK and Novartis reinforced commitments on Thursday to tackle neglected tropical diseases, as world leaders and health experts gather in Rwanda to discuss ways to better combat illnesses affecting more than a billion people, mostly in impoverished communities. GSK pledged to spend 1 billion pounds ($1.23 billion) over the next decade on developing medicines and vaccines to tackle neglected tropical diseases (NTDs), as well as infectious diseases such as malaria, tuberculosis and HIV, which disproportionately affect lower-income countries. The London-based company, which pioneered the first malaria vaccine, has carved out, and will invest in, a specific global health unit that will not generate a profit for GSK.